Long-term consequences of type 2 diabetes mellitus: Economic impact on society and managed care

American Journal of Managed Care

Volumn 8, Issue 16 SUPPL., 2002, Pages

  Killilea, Terrance ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; ANTIINFECTIVE AGENT; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DERMATOLOGICAL AGENT; GASTROINTESTINAL AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HORMONE; INSULIN; METFORMIN; PLACEBO; RESPIRATORY TRACT AGENT; SULFONYLUREA;

BEHAVIOR MODIFICATION; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITION; COMORBIDITY; COST CONTROL; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CLASSIFICATION; ECONOMIC ASPECT; EYE DISEASE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; LENGTH OF STAY; LIFESTYLE; LONG TERM CARE; MANAGED CARE; MENTAL HEALTH; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL NEUROPATHY; PHYSICAL ACTIVITY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROTEINURIA; QUALITY OF LIFE; REVIEW; RISK FACTOR; SOCIETY; UNITED STATES;

COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; MANAGED CARE PROGRAMS; QUALITY OF LIFE; UNITED STATES;

EID: 0036806076     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Centers for Disease Control and Prevention. National diabetes fact sheet. General information and national estimates on diabetes in the United States, 2000. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2002. Available at: www.cdc.gov/od/oc/media/fact/diabetes.htm. Accessed June 26, 2002.
2. Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med. 1998;158:134-140.
3. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
4. Hillier TA, Pedula KL. Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care. 2001;24:1522-1527.
5. Bagust A, Hopkinson PK, Maslove L, Downs KE, Harrison DJ. Future prevalence and economic burden of type 2 diabetes in the United States to 2050 [abstract 838-P]. Diabetes. 2001;50(suppl 2):A205.
6. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2002;25(suppl 1):S5-S20.
7. Marrero DG. Current effectiveness of diabetes health care in the US: how far from the ideal? Diabetes Rev. 1994;2:292-309.
8. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790-797.
9. Knowler WC, Barrett-Connor E, Fowler SE, et al, for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
10. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581.
11. Brown JB, Nichols GA, Glauber HS, Bakst AW, Schaeffer M, Kelleher CC. Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus. Am J Health-Syst Pharm. 2001;58:151-157.
12. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care. 1999;22(suppl 3):C10-C13.
13. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453-458.
14. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 2000;283:221-228.
15. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24:1476-1485.
16. Adler AI, Neil HA, Manley SE, Holman RR, Turner RC. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). Am Heart J. 1999;138:S353-S359.
17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
18. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
19. Mukamal KJ, Nesto RW, Cohen MC, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care. 2001;24:1422-1427.
20. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24:1614-1619.
21. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-713.
22. Donnan PT, Leese GP, Morris AD, for the Diabetes Audit and Research in Tayside, Scotland/Medicine Monitoring Unit Collaboration. Hospitalizations for people with type 1 and type 2 diabetes compared with the nondiabetic population of Tayside, Scotland: a retrospective cohort study of resource use. Diabetes Care. 2000;23:1774-1779.
23. Erkens JA, Klungel OH, Stolk RP, Spoelstra JA, Grobbee DE, Leufkens HG. Cardiovascular drug use and hospitalizations attributable to type 2 diabetes. Diabetes Care. 2001;24:1428-1432.
24. Evans JM, MacDonald TM, Leese GP, Ruta DA, Morris AD. Impact of type 1 and type 2 diabetes on patterns and costs of drug prescribing: a population-based study. Diabetes Care. 2000;23:770-774.
25. Currie CJ, McEwan P, Hopkinson P, Peters JR. The relationship between cardiovascular risk and hospital bed utilisation in people with type 2 diabetes [abstract 971]. Diabetologia. 2001;44(suppl 1):A253.
26. Brown JB, Nichols GA, Glauber HS, Bakst AW. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care. 1999;22:1116-1124.
27. Downs KE, Harrison DJ, Eaton S. High outpatient costs for people with diabetes are driven by number of visits [abstract 1040-P]. Diabetes. 2001;50(suppl 2): A253.
28. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab. 1994;78:809A-809F.
29. Nicodemus KK, Folsom AR, Iowa Women's Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001;24:1192-1197.
30. Ferrara A, Karter AJ, Ackerson LM, Liu JY, Selby JV, and The Northern California Kaiser Permanente Diabetes Registry. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes. Diabetes Care. 2001;24:1144-1150.
31. Grodstein F, Chen J, Wilson RS, Manson JE, for the Nurse's Health Study. Type 2 diabetes and cognitive function in community-dwelling elderly women. Diabetes Care. 2001;24:1060-1065.
32. Bagust A, Hopkinson PK, Mera R, Bakst AW, Currie C. Type 2 diabetes impact on quality-adjusted life expectancy [abstract 973]. Diabetologia. 2001;44(suppl 1):A253.
33. Mera R, Bakst AW, Auland M. Quality of life in type 2 diabetes: the CODE-2 experience [abstract 967]. Diabetologia. 2001;44(suppl 1):A252.
34. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA. 1998;280:1490-1496.
35. Koopmanschap M. Coping with type II diabetes: the patient's perspective. Diabetologia. 2002;45:S18-S22.
36. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001;285:182-189.